Oncology Institute (NASDAQ:TOI) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
by Renee Jackson · The Cerbat GemOncology Institute (NASDAQ:TOI – Get Free Report) posted its earnings results on Thursday. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05, FiscalAI reports. The firm had revenue of $147.44 million for the quarter, compared to analysts’ expectations of $142.10 million.
Here are the key takeaways from Oncology Institute’s conference call:
- Q1 results and guidance reaffirmed: Revenue rose 41% YoY to $147.4M, adjusted EBITDA improved (Q1 loss narrowed) and management reaffirmed full‑year revenue guidance of $630–650M while raising free cash flow guidance to a positive $5M–$15M.
- Specialty pharmacy is the primary growth engine: Pharmacy revenue grew 78% to $87.5M with record fills and $16.8M gross profit; gross margin held at ~19.2% and management expects additional Part D tailwinds from expanded pharmacy access in Florida in H2.
- Florida delegated capitation scale and profitability: The Florida market is now profitable, and TOI plans to be network‑adequate across 25 counties serving ~200,000 MA lives under delegated capitation by July 1, with seven new clinics planned to support that growth.
- Shift toward capitated/value‑based mix has mixed margin effects: Capitated revenue grew 54% and now represents ~45.6% of patient services, but patient services gross margin fell (9.7% vs. 11.3% a year ago) due to ramping delegated contracts and conservative reserves.
- Operational efficiency and balance‑sheet actions underway: TOI is on track for $2M of 2026 OpEx savings from AI pilots, SG&A leverage improved (19.1% of revenue), cash was $30.3M at quarter end, and management is in late‑stage discussions to refinance the $85.9M convertible note.
Oncology Institute Stock Performance
Oncology Institute stock traded down $0.07 during trading on Friday, reaching $4.00. The company had a trading volume of 2,442,939 shares, compared to its average volume of 1,888,234. The firm’s 50-day simple moving average is $3.21 and its 200 day simple moving average is $3.35. Oncology Institute has a 1-year low of $2.02 and a 1-year high of $4.88. The firm has a market capitalization of $395.36 million, a PE ratio of -7.14 and a beta of 0.33.
Wall Street Analyst Weigh In
TOI has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a report on Monday, April 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. B. Riley Financial lifted their target price on shares of Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.00.
View Our Latest Stock Report on Oncology Institute
Insiders Place Their Bets
In related news, major shareholder Jorey Chernett purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were purchased at an average price of $3.10 per share, with a total value of $62,000.00. Following the purchase, the insider owned 10,499,358 shares of the company’s stock, valued at $32,548,009.80. The trade was a 0.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mohit Kaushal sold 38,433 shares of Oncology Institute stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $3.50, for a total transaction of $134,515.50. Following the completion of the sale, the director directly owned 172,583 shares in the company, valued at $604,040.50. This represents a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders purchased a total of 568,985 shares of company stock worth $1,759,601 in the last three months. 8.50% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Oncology Institute
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC acquired a new stake in Oncology Institute during the 4th quarter worth $31,000. Cetera Investment Advisers boosted its stake in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the last quarter. State of Wyoming acquired a new stake in Oncology Institute during the 2nd quarter worth $37,000. Prelude Capital Management LLC acquired a new stake in Oncology Institute during the 3rd quarter worth $41,000. Finally, BNP Paribas Financial Markets boosted its stake in Oncology Institute by 141.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,119 shares of the company’s stock worth $42,000 after purchasing an additional 7,091 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.
Oncology Institute Company Profile
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.